Redox control of cancer cell destruction
- PMID: 29477046
- PMCID: PMC5842284
- DOI: 10.1016/j.redox.2018.01.015
Redox control of cancer cell destruction
Abstract
Redox regulation has been proposed to control various aspects of carcinogenesis, cancer cell growth, metabolism, migration, invasion, metastasis and cancer vascularization. As cancer has many faces, the role of redox control in different cancers and in the numerous cancer-related processes often point in different directions. In this review, we focus on the redox control mechanisms of tumor cell destruction. The review covers the tumor-intrinsic role of oxidants derived from the reduction of oxygen and nitrogen in the control of tumor cell proliferation as well as the roles of oxidants and antioxidant systems in cancer cell death caused by traditional anticancer weapons (chemotherapeutic agents, radiotherapy, photodynamic therapy). Emphasis is also put on the role of oxidants and redox status in the outcome following interactions between cancer cells, cytotoxic lymphocytes and tumor infiltrating macrophages.
Keywords: Antioxidants; Cancer; Chemotherapeutics; Cytotoxic lymphocytes; Free radicals; Natural killer cells; Redox regulation.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Figures



Similar articles
-
Reactive oxygen species in redox cancer therapy.Cancer Lett. 2015 Oct 10;367(1):18-25. doi: 10.1016/j.canlet.2015.07.008. Epub 2015 Jul 14. Cancer Lett. 2015. PMID: 26187782 Review.
-
Experimental therapeutics: targeting the redox Achilles heel of cancer.Curr Opin Investig Drugs. 2007 Dec;8(12):1022-37. Curr Opin Investig Drugs. 2007. PMID: 18058573 Review.
-
Reactive Oxygen and Nitrogen Species-Induced Protein Modifications: Implication in Carcinogenesis and Anticancer Therapy.Cancer Res. 2018 Nov 1;78(21):6040-6047. doi: 10.1158/0008-5472.CAN-18-0980. Epub 2018 Oct 16. Cancer Res. 2018. PMID: 30327380 Review.
-
Targeting Production of Reactive Oxygen Species as an Anticancer Strategy.Anticancer Res. 2021 Dec;41(12):5881-5902. doi: 10.21873/anticanres.15408. Anticancer Res. 2021. PMID: 34848443 Review.
-
The redox-active nanomaterial toolbox for cancer therapy.Cancer Lett. 2015 Apr 1;359(1):9-19. doi: 10.1016/j.canlet.2015.01.013. Epub 2015 Jan 15. Cancer Lett. 2015. PMID: 25597786 Review.
Cited by
-
The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057. Cancers (Basel). 2021. PMID: 33923319 Free PMC article. Review.
-
Cerium Oxide Nanoparticles Re-establish Cell Integrity Checkpoints and Apoptosis Competence in Irradiated HaCat Cells via Novel Redox-Independent Activity.Front Pharmacol. 2018 Oct 16;9:1183. doi: 10.3389/fphar.2018.01183. eCollection 2018. Front Pharmacol. 2018. PMID: 30459604 Free PMC article.
-
Electronic effects on the mechanism of the NAD+ coenzyme reduction catalysed by a non-organometallic ruthenium(ii) polypyridyl amine complex in the presence of formate.RSC Adv. 2022 Aug 1;12(33):21191-21202. doi: 10.1039/d2ra01890j. eCollection 2022 Jul 21. RSC Adv. 2022. PMID: 35975079 Free PMC article.
-
A Nudibranch Marine Extract Selectively Chemosensitizes Colorectal Cancer Cells by Inducing ROS-Mediated Endoplasmic Reticulum Stress.Front Pharmacol. 2021 Apr 8;12:625946. doi: 10.3389/fphar.2021.625946. eCollection 2021. Front Pharmacol. 2021. PMID: 34456713 Free PMC article.
-
Polymeric persulfide prodrugs: Mitigating oxidative stress through controlled delivery of reactive sulfur species.ACS Macro Lett. 2020 Apr 21;9(4):606-612. doi: 10.1021/acsmacrolett.0c00118. Epub 2020 Apr 7. ACS Macro Lett. 2020. PMID: 33194315 Free PMC article.
References
-
- Simeone E., Ascierto P.A. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J. Immunotoxicol. 2012;9(3):241–247. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials